At a Glance
- Companies: Cellares and TScan Therapeutics
- Therapy: TSC-101
- Disease area: Haematologic malignancies
- Focus: Automated cell therapy manufacturing
- Next steps: Evaluate process development and manufacturability
What happened?
Cellares and TScan Therapeutics have agreed to evaluate automated manufacturing for TSC-101, a T-cell receptor-engineered cell therapy in development for patients with haematologic malignancies. The collaboration aims to see whether Cellares’ automated platform can support scalable production of the therapy.
Why does it matter?
Cell therapies are powerful but difficult and expensive to manufacture, especially when each product must be made with highly controlled, bespoke processes. If automation works for TSC-101, it could reduce complexity and make the therapy easier to scale for patients who need it after allogeneic bone marrow transplantation.
Who’s behind it?
TScan Therapeutics is developing TSC-101 for use after allogeneic haemopoietic cell transplantation, where it is intended to eliminate residual disease and prevent relapse. Cellares is a cell-therapy manufacturing company focused on fully automated production systems for advanced therapies.
How was it achieved?
The agreement will assess whether TSC-101 can be manufactured on Cellares’ automated platform without compromising product quality or clinical usability. This is part of a broader trend in cell therapy toward standardising and scaling production through automation rather than manual, site-specific workflows.
What’s next?
The companies will now evaluate the fit between the therapy and the manufacturing system, likely focusing on process robustness, product consistency and commercial scalability. If successful, the approach could support future clinical and eventual commercial supply.